Diaceutics (LSE:DXRX), the precision medicine data and services company, has drawn attention in recent months after reporting a sharp increase in recurring revenue. In a trading update for the half year ended 30 June 2026, published in late July, the company reported a 75% rise in annual Recurring Revenue (ARR) and 22% revenue growth. The announcement itself was headlined around ARR growth driving revenue and profit visibility.
With full interim results expected, investors following healthcare technology names on the FTSE AIM All Share index are watching to see whether that momentum is reflected in the detailed figures.
What the Company Does
Diaceutics works with pharmaceutical companies to help bring precision medicines and their associated diagnostic tests to patients. Precision therapies often depend on a test to identify suitable patients, and delays in testing can slow the uptake of new drugs. The company's core platform, DXRX - The Diagnostic Network, combines laboratory data, analytics and services to help pharmaceutical clients plan and monitor diagnostic testing for their therapies.
Latest Developments
The half-year update was set against the company's Precision for All strategy, which is linked to market expansion. The shift towards recurring revenue is significant because subscription-style income tends to be more predictable than one-off project work, which has historically formed a large part of revenue for many pharmaceutical services businesses.
Diaceutics has also announced an expansion of its multi-year Relay Partnership with Syndax, a US biopharmaceutical company, according to a statement on its website. Partnerships of this kind give an indication of how pharmaceutical customers are adopting the company's platform over longer contract periods.
Earlier in the year, the company published final results for 2025 on 26 May 2026, then posted its 2025 Annual Report and set the date for its 2026 annual general meeting. At the time of the full-year figures, Diaceutics said its order book and pipeline provided confidence for 2026.
Financial Picture
The headline growth rates from the half-year update are encouraging, but detailed profit, cash and Margin figures were not available at the time of writing. Investors may wish to consult the original announcements for absolute revenue and ARR values. No Dividend information was identified, which is typical for a growth-stage company reinvesting in its platform. The company has also filed routine block listing returns relating to shares that may be issued under employee incentive schemes.
Sector and Index Context
Precision medicine continues to be an important area of pharmaceutical research, particularly in oncology, where many new therapies are targeted at patients with specific biomarkers. Companies that help resolve testing bottlenecks can benefit as more targeted drugs reach market. However, pharmaceutical spending on commercial services can be affected by budget cycles, drug pipeline setbacks and industry consolidation. Diaceutics is one of a number of healthcare technology companies within the FTSE AIM All Share Index.
Key Risks
Key risks include the concentration of revenue among large pharmaceutical customers, the timing of contract signings, the possibility that clinical or regulatory setbacks in client drug programmes reduce demand, and competition from other data and analytics providers. Converting ARR growth into sustained profitability is also a central test for the business.
What to Watch Next
Ahead of the interim results, investors were looking for clarity on several points. Attention is likely to fall on the quality and visibility of recurring revenue, progress on profitability, cash generation, new and expanded pharmaceutical partnerships, and any update to guidance for the full 2026 financial year.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...